Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Pembrolizumab
Keytruda
Not routinely available
SMC (SMC2688)
04/12/2024
Indication
In combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, for the treatment of resectable non-small cell lung carcinoma at high risk of recurrence in adults.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Not routinely available as not recommended for use in NHSScotland
Formulation
Concentrate for solution for infusion
Comments
Link to Advice
Advice Published
11/11/2024
SMC Submission Type
Full
SMC Status
Not recommended